Stemline Therapeutics

ELZONRIS

Manufacturer:

Stemline Therapeutics

Elzonris HCPCS:

J9269

HCPCS Code Descriptor:

Injection, tagraxofusp-erzs, 10 micrograms

Category:

J Code

Elzonris NDCs:

72187-0401-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Elzonris CPT Codes:

Potential CPT administration codes for Elzonris can be found at the following link.

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Elzonris:

ELZONRIS is an Oncology drug manufactured by Stemline Therapeutics and administered via the Intravenous route of administration. The J Code: J9269 is aligned to the drug ELZONRIS.

ACCESS PRICING AND MORE BY REGISTERING

J9269 Added Date:

October 1, 2019

J9269 Effective Date:

October 1, 2019

J9269 Termination Date:

HCPCS Active

Elzonris billing and coding information can be found through Stemline Therapeutics at the link below:
Our team did not identify a source for Elzonris patient assistance information. Please reach out to our team if you feel that this is a mistake.
ELZONRIS prescribing information can be found at the link below:
Information regarding ELZONRIS’s side effects can be found at MedlinePlus